Osteoporosis International

, Volume 29, Issue 8, pp 1827–1832 | Cite as

Low rates of osteoporosis treatment after hospitalization for hip fracture in Hawaii

  • E.T. Nguyen
  • T. Posas-Mendoza
  • A.M. Siu
  • H.J. Ahn
  • S.Y. Choi
  • S.Y. LimEmail author
Original Article



We evaluated osteoporosis treatment and DEXA utilization rates of patients who were admitted for hip fracture in a single healthcare system in Hawaii from 2015 to 2016. We found that osteoporosis treatment and DEXA utilization rates were low, highlighting a critical gap in osteoporosis care after admission for hip fracture.


The objective of this study was to evaluate osteoporosis care after an admission for hip fracture at three community hospitals within a single healthcare system in Hawaii.


A retrospective chart review was conducted (n = 428) of patients ≥ 50 years and hospitalized for hip fractures between January 1, 2015, and May 31, 2016, at three major hospitals within Hawaii Pacific Health, a large healthcare system in Hawaii. Basic demographics were collected, and medications prescribed were quantified and described within 1 year of hip fracture. Logistic regression was used to evaluate the association between collected variables and the odds of osteoporosis treatment.


Only 115 (26.9%) patients were prescribed a medication for osteoporosis as a secondary prevention within a year of hospitalization for hip fracture. DEXA scans were performed in 137 (32.0%) patients. Most of the treated patients were prescribed oral bisphosphonates. Treatment facility, female gender, and higher BMI were found to be predictive factors for osteoporosis treatment.


The use of osteoporosis medication for secondary prevention after admission for hip fracture in Hawaii is low. Efforts need to be made to improve treatment rates, especially among males.


Hip fracture Hospitalization Osteoporosis Secondary prevention 



The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.


The biostatisticians are partially supported by the National Institute on Minority Health and Health Disparities (U54MD00760131).

Compliance with ethical standards

Conflicts of interest



  1. 1.
    Lim SY, Bolster MB (2015) Current approaches to osteoporosis treatment. Curr Opin Rheumatol 27:216–224CrossRefPubMedGoogle Scholar
  2. 2.
    Cummings SR, Melton LJ (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359:1761–1767CrossRefPubMedGoogle Scholar
  3. 3.
    Foster K (2017) Hip fractures in adults. UpToDate, WalthamGoogle Scholar
  4. 4.
    Colon-Emeric CS, Sloane R, Hawkes WG, Magaziner J, Zimmerman SI, Pieper CF, Lyles KW (2000) The risk of subsequent fractures in community-dwelling men and male veterans with hip fracture. Am J Med 109:324–326CrossRefPubMedGoogle Scholar
  5. 5.
    Drew S, Judge A, Cooper C, Javaid M, Farmer A, Gooberman-Hill R (2016) Secondary prevention of fractures after hip fracture: a qualitative study of effective service delivery. Osteoporos Int 27:1719–1727CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Sale JE, Beaton D, Bogoch E (2014) Secondary prevention after an osteoporosis-related fracture: an overview. Clin Geriatr Med 30:317–332CrossRefPubMedGoogle Scholar
  7. 7.
    Harrington JT, Broy SB, Derosa AM, Licata AA, Shewmon DA (2002) Hip fracture patients are not treated for osteoporosis: a call to action. Arthritis Care Res 47:651–654CrossRefGoogle Scholar
  8. 8.
    MacLean C, Newberry S, Maglione M, McMahon M, Ranganath V, Suttorp M, Mojica W, Timmer M, Alexander A, McNamara M (2008) Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis preventing fractures in people with low bone density or osteoporosis. Ann Intern Med 148:197–213CrossRefPubMedGoogle Scholar
  9. 9.
    Kim SC, Kim M-S, Sanfélix-Gimeno G, Song HJ, Liu J, Hurtado I, Peiró S, Lee J, Choi N-K, Park B-J (2015) Use of osteoporosis medications after hospitalization for hip fracture: a cross-national study. Am J Med 128:519–526. e511CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Dickson M, Plauschinat CA (2008) Racial differences in medication compliance and healthcare utilization among hypertensive Medicaid recipients: fixed-dose vs free-combination treatment. Ethn Dis 18:204–209PubMedGoogle Scholar
  11. 11.
    Varney JM, Okamoto GA, Goebert DA (1992) Hospitalizations for hip fractures among elderly persons in Hawaii, 1986-1990. Arch Phys Med Rehabil 73:752–757PubMedGoogle Scholar
  12. 12.
    Gerber BS, Cho YI, Arozullah AM, Lee SY (2010) Racial differences in medication adherence: a cross-sectional study of Medicare enrollees. Am J Geriatr Pharmacother 8:136–145CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Hamrick I, Whetstone LM, Cummings DM (2006) Racial disparity in treatment of osteoporosis after diagnosis. Osteoporos Int 17:1653–1658CrossRefPubMedGoogle Scholar
  14. 14.
    Tanne JH (2007) Is Wisconsin or Hawaii the healthiest US state? BMJ 334:1293PubMedPubMedCentralGoogle Scholar
  15. 15.
    Hawaii Pacific Health (2017) Hawaii Pacific Health—about us. Accessed 20 Nov 2017
  16. 16.
    McClung MR, Grauer A, Boonen S et al (2014) Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370:412–420CrossRefPubMedGoogle Scholar
  17. 17.
    Solomon DH, Johnston SS, Boytsov NN, McMorrow D, Lane JM, Krohn KD (2014) Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011. J Bone Miner Res 29:1929–1937CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Weaver J, Sajjan S, Lewiecki EM, Harris ST (2017) Diagnosis and treatment of osteoporosis before and after fracture: a side-by-side analysis of commercially insured and Medicare advantage osteoporosis patients. J Manag Care Spec Pharm 23:735–744CrossRefPubMedGoogle Scholar
  19. 19.
    Antonelli M, Einstadter D, Magrey M (2014) Screening and treatment of osteoporosis after hip fracture: comparison of sex and race. J Clin Densitom 17:479–483CrossRefPubMedGoogle Scholar
  20. 20.
    Gillespie CW, Morin PE (2017) Trends and disparities in osteoporosis screening among women in the United States, 2008-2014. Am J Med 130:306–316CrossRefPubMedGoogle Scholar
  21. 21.
    Kaufman JD, Bolander ME, Bunta AD, Edwards BJ, Fitzpatrick LA, Simonelli C (2003) Barriers and solutions to osteoporosis care in patients with a hip fracture. J Bone Joint Surg Am 85-A:1837–1843CrossRefPubMedGoogle Scholar
  22. 22.
    Sale J, Bogoch E, Hawker G, Gignac M, Beaton D, Jaglal S, Frankel L (2014) Patient perceptions of provider barriers to post-fracture secondary prevention. Osteoporos Int 25:2581–2589CrossRefPubMedGoogle Scholar
  23. 23.
    Beaton D, Dyer S, Jiang D, Sujic R, Slater M, Sale J, Bogoch E, Team OFCSPE (2014) Factors influencing the pharmacological management of osteoporosis after fragility fracture: results from the Ontario osteoporosis strategy’s fracture clinic screening program. Osteoporos Int 25:289–296CrossRefPubMedGoogle Scholar
  24. 24.
    Yu J, Brenneman SK, Sazonov V, Modi A (2015) Reasons for not initiating osteoporosis therapy among a managed care population. Patient Prefer Adherence 9:821PubMedPubMedCentralGoogle Scholar
  25. 25.
    Marsh D, Akesson K, Beaton DE et al (2011) Coordinator-based systems for secondary prevention in fragility fracture patients. Osteoporos Int 22:2051–2065CrossRefPubMedGoogle Scholar
  26. 26.
    Newman ED (2011) Perspectives on pre-fracture intervention strategies: the Geisinger health system osteoporosis program. Osteoporos Int 22(Suppl 3):451–455CrossRefPubMedGoogle Scholar
  27. 27.
    Dell R (2011) Fracture prevention in Kaiser Permanente Southern California. Osteoporos Int 22(Suppl 3):457–460CrossRefPubMedGoogle Scholar
  28. 28.
    Cawthon PM (2011) Gender differences in osteoporosis and fractures. Clin Orthop Relat Res 469:1900–1905CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Mendelson DA, Friedman SM (2014) Principles of comanagement and the geriatric fracture center. Clin Geriatr Med 30:183–189CrossRefPubMedGoogle Scholar
  30. 30.
    Counterweight Project Te (2005) The impact of obesity on drug prescribing in primary care. Br J Gen Pract 55:743–749Google Scholar
  31. 31.
    Cowie MR, Blomster JI, Curtis LH, Duclaux S, Ford I, Fritz F, Goldman S, Janmohamed S, Kreuzer J, Leenay M, Michel A, Ong S, Pell JP, Southworth MR, Stough WG, Thoenes M, Zannad F, Zalewski A (2017) Electronic health records to facilitate clinical research. Clin Res Cardiol 106:1–9CrossRefPubMedGoogle Scholar
  32. 32.
    Terry AL, Chevendra V, Thind A, Stewart M, Marshall JN, Cejic S (2010) Using your electronic medical record for research: a primer for avoiding pitfalls. Fam Pract 27:121–126CrossRefPubMedGoogle Scholar
  33. 33.
    Vassar M, Holzmann M (2013) The retrospective chart review: important methodological considerations. J Educ Eval Health Prof 10:12CrossRefPubMedGoogle Scholar
  34. 34.
    Gilbert EH, Lowenstein SR, Koziol-McLain J, Barta DC, Steiner J (1996) Chart reviews in emergency medicine research: where are the methods? Ann Emerg Med 27:305–308CrossRefPubMedGoogle Scholar
  35. 35.
    Lim SY, Lu N, Oza A, Fisher M, Rai SK, Menendez ME, Choi HK (2016) Trends in gout and rheumatoid arthritis hospitalizations in the United States, 1993-2011. JAMA 315:2345–2347CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2018

Authors and Affiliations

  • E.T. Nguyen
    • 1
  • T. Posas-Mendoza
    • 2
  • A.M. Siu
    • 3
  • H.J. Ahn
    • 4
  • S.Y. Choi
    • 4
  • S.Y. Lim
    • 5
    Email author
  1. 1.Lewis and Clark CollegePortlandUSA
  2. 2.Department of Internal MedicineUniversity of HawaiiHonoluluUSA
  3. 3.Hawaii Pacific Health Research InstituteHonoluluUSA
  4. 4.Department of Complementary and Integrative MedicineUniversity of HawaiiHonoluluUSA
  5. 5.Hawaii Pacific Health, Bone and Joint CenterStraub ClinicHonoluluUSA

Personalised recommendations